FDA approves Bristol-Myers’s skin cancer treatment Opdivo By: MarketWatch December 22, 2014 at 18:09 PM EST Company expected to charge $12,500 a month for drug to fight lethal late stage melanoma. Read More >> Related Stocks: Bristol-Myers Squibb Merck & Co